|
|
Volumn 48, Issue 3, 1998, Pages 344-345
|
|
Comment on: A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHNCA) protocol 5-85 [2] (multiple letters)
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ETANIDAZOLE;
NIMORAZOLE;
PLACEBO;
RADIOSENSITIZING AGENT;
CANCER RADIOTHERAPY;
CLINICAL PROTOCOL;
CLINICAL TRIAL;
CONTROLLED STUDY;
DENMARK;
DOUBLE BLIND PROCEDURE;
HEAD AND NECK CANCER;
HUMAN;
HYPOXIC CELL;
LARYNX CARCINOMA;
LETTER;
MAJOR CLINICAL STUDY;
PHARYNX CARCINOMA;
PHASE 3 CLINICAL TRIAL;
PRIORITY JOURNAL;
RADIATION DOSE;
RADIOSENSITIZATION;
RANDOMIZED CONTROLLED TRIAL;
TREATMENT OUTCOME;
HUMANS;
LARYNGEAL NEOPLASMS;
NIMORAZOLE;
PHARYNGEAL NEOPLASMS;
RADIATION-SENSITIZING AGENTS;
|
|
EID: 0031731921
PISSN: 01678140
EISSN: None
Source Type: Journal
DOI: 10.1016/S0167-8140(98)00085-1 Document Type: Letter |
|
Times cited : (3)
|
|
References (0)
|
